Team:USTC CHINA/Project/ProjectDetails/Background
From 2013.igem.org
(Difference between revisions)
(23 intermediate revisions not shown) | |||
Line 10: | Line 10: | ||
<div id="igemlogo"><a href="https://2013.igem.org/Main_Page" target="_blank"><img src="https://static.igem.org/mediawiki/2013/2/26/2013ustcigem_IGEM_basic_Logo.png" alt="igem home page" width="50" height="40" /></a></div> | <div id="igemlogo"><a href="https://2013.igem.org/Main_Page" target="_blank"><img src="https://static.igem.org/mediawiki/2013/2/26/2013ustcigem_IGEM_basic_Logo.png" alt="igem home page" width="50" height="40" /></a></div> | ||
- | + | <ul id="nav"> | |
- | + | ||
<li><a href="https://2013.igem.org/Team:USTC_CHINA">Home</a></li> | <li><a href="https://2013.igem.org/Team:USTC_CHINA">Home</a></li> | ||
<li class="active"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Project</a> | <li class="active"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Project</a> | ||
<ul class="subs"> | <ul class="subs"> | ||
<li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Overview</a></li> | <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Overview</a></li> | ||
- | <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/ | + | <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Background">Background</a></li> |
+ | <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Design">Design</a></li> | ||
<li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Results</a></li> | <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Results</a></li> | ||
- | <li><a href="https://2013.igem.org/Team:USTC_CHINA | + | <li><a href="https://2013.igem.org/Team:USTC_CHINA/Parts">Parts</a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
Line 29: | Line 29: | ||
<li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/">Modeling</a> | <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/">Modeling</a> | ||
<ul class="subs"> | <ul class="subs"> | ||
- | <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/ | + | <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/KillSwitch">Kill Switch</a></li> |
<li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/B.SubtilisCulture">B.Subtilis Culture</a></li> | <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/B.SubtilisCulture">B.Subtilis Culture</a></li> | ||
- | <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/ | + | <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/DesignsofImmuneExperiments">Designs of Immune Experiments</a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
Line 40: | Line 40: | ||
</ul> | </ul> | ||
</li> | </li> | ||
- | <li><a href="https://2013.igem.org/Team:USTC_CHINA/ | + | <li><a href="https://2013.igem.org/Team:USTC_CHINA/Team">Team</a> |
<ul class="subs"> | <ul class="subs"> | ||
- | <li><a href="https://2013.igem.org/Team:USTC_CHINA/ | + | <li><a href="https://2013.igem.org/Team:USTC_CHINA/Team">Members</a></li> |
<li><a href="https://igem.org/Team.cgi?year=2013&team_name=USTC_CHINA">Profile</a></li> | <li><a href="https://igem.org/Team.cgi?year=2013&team_name=USTC_CHINA">Profile</a></li> | ||
- | <li><a href="https://2013.igem.org/Team:USTC_CHINA/ | + | <li><a href="https://2013.igem.org/Team:USTC_CHINA/Attributions">Attributions</a></li> |
- | <li><a href="https:// | + | <li><a href="https://igem.org/2013_Judging_Form?id=1074#iGEM_Medals">Achievements</a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
<li><a href="https://2013.igem.org/Team:USTC_CHINA/Safety">Safety</a></li> | <li><a href="https://2013.igem.org/Team:USTC_CHINA/Safety">Safety</a></li> | ||
- | + | </ul> | |
<div id="tlogo"><img src="https://static.igem.org/mediawiki/2013/f/f8/2013ustc-china_T-VACCINE.png" width="100%" height="123" /> | <div id="tlogo"><img src="https://static.igem.org/mediawiki/2013/f/f8/2013ustc-china_T-VACCINE.png" width="100%" height="123" /> | ||
</div> | </div> | ||
Line 61: | Line 61: | ||
<div class="leftbar" align="left"> | <div class="leftbar" align="left"> | ||
<div class="basic-bar"> | <div class="basic-bar"> | ||
- | <h1> | + | <h1>Background</h1> |
<h2>ONE:Why We Want to Design T-Vaccine?<h2> | <h2>ONE:Why We Want to Design T-Vaccine?<h2> | ||
<p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries.<p> | <p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries.<p> | ||
<h3>the Comparison of Different Vaccine Delivery Ways<h3> | <h3>the Comparison of Different Vaccine Delivery Ways<h3> | ||
- | + | <img src="https://static.igem.org/mediawiki/2013/c/c1/Traditional_needles.png" width="600" height="375" /> | |
- | <img src="https://static.igem.org/mediawiki/2013/ | + | <img src="https://static.igem.org/mediawiki/2013/c/c3/Traditional_transdermal_methods.png" width="600" height="375" /> |
+ | <img src="https://static.igem.org/mediawiki/2013/6/69/T-vaccine.png" width="600" height="475" /> | ||
+ | |||
<p>So the key to solve these problems is to create a new way to both decrease the cost and deliver vaccine harmlessly. That is what we are working for, T-Vaccine.<p> | <p>So the key to solve these problems is to create a new way to both decrease the cost and deliver vaccine harmlessly. That is what we are working for, T-Vaccine.<p> | ||
<h2>TWO:What We Are Trying To Do.<h2> | <h2>TWO:What We Are Trying To Do.<h2> | ||
Line 74: | Line 76: | ||
<p>When this idea first stroke us, it seemed amazing that our dream is so naïve and unpractical. Above all, how can we make antigen get through the skin barrier? We refer to various transdermal methods, like Iontophoresis, Sonophoresis, Microneedle. They require special equipment and deal damage to skin. Our idea remained unrealistic until we find Transdermal peptide 1.<p> | <p>When this idea first stroke us, it seemed amazing that our dream is so naïve and unpractical. Above all, how can we make antigen get through the skin barrier? We refer to various transdermal methods, like Iontophoresis, Sonophoresis, Microneedle. They require special equipment and deal damage to skin. Our idea remained unrealistic until we find Transdermal peptide 1.<p> | ||
<p>TD-1 is an eleven amino acid peptide, which can greatly facilitate macromolecule transdermal delivery through intact skin. This was first discovered by professor Wen Longping in our university and the results were published on Nature biotechnology.<p> | <p>TD-1 is an eleven amino acid peptide, which can greatly facilitate macromolecule transdermal delivery through intact skin. This was first discovered by professor Wen Longping in our university and the results were published on Nature biotechnology.<p> | ||
- | + | TD1 Sequence<br> | |
- | + | <img src="https://static.igem.org/mediawiki/2013/9/97/%E9%80%8F%E7%9A%AE%E8%82%BD%E5%BA%8F%E5%88%97.png" width="580" height="50" /> | |
+ | Title of Nature Letter About TD1<br> | ||
+ | <img src="https://static.igem.org/mediawiki/2013/a/a7/Nature.png" width="580" height="400" /> | ||
<h3>2. the Principle of TD1:<h3> | <h3>2. the Principle of TD1:<h3> | ||
<p>The biggest challenge of penetrating the skin is epidermis of skin barrier. Traditional transdermal methods have to break the epidermis, though it maybe painless, the injury still have the potential of infection. On the contrary, TD1 is painless and harmless to skin, it could open the skin channels shortly, so not only molecules but also filobactivirus could penetrate the skin and go into the blood circulation system.<p> | <p>The biggest challenge of penetrating the skin is epidermis of skin barrier. Traditional transdermal methods have to break the epidermis, though it maybe painless, the injury still have the potential of infection. On the contrary, TD1 is painless and harmless to skin, it could open the skin channels shortly, so not only molecules but also filobactivirus could penetrate the skin and go into the blood circulation system.<p> | ||
- | + | Filamentous Phage <br> | |
- | + | <img src="https://static.igem.org/mediawiki/2013/8/81/%E4%B8%9D%E7%8A%B6%E5%99%AC%E8%8F%8C%E4%BD%93.png" width="580" height="500" /> | |
- | + | Skin<br> | |
+ | <img src="https://static.igem.org/mediawiki/2013/2/27/Skin.png" width="580" height="500" /> | ||
+ | eGFP Transdermal<br> | ||
+ | <img src="https://static.igem.org/mediawiki/2013/f/f6/Time_-GFP.png" width="580" height="500" /> | ||
+ | |||
- | |||
- | |||
- | |||
- | |||
</div> | </div> | ||
Line 99: | Line 103: | ||
</div> | </div> | ||
<div class="rightbar"> | <div class="rightbar"> | ||
- | <div class="port-sidebar-border"><h> | + | <div class="port-sidebar-border"><h>Project</h></div> |
<div class="clear"></div> | <div class="clear"></div> | ||
<div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Overview</a></div> | <div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Overview</a></div> | ||
Line 107: | Line 111: | ||
<div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Results</a></div> | <div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Results</a></div> | ||
<div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Basic Experiment</a></div> | <div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Basic Experiment</a></div> | ||
- | <div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results/ | + | <div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results/FurtherWork">Further Work</a></div> |
- | <div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA | + | <div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Parts">Parts</a></div> |
Latest revision as of 17:44, 27 September 2013